None
Conditions
Interventions
Group B:In Group B, the RASS-PAL sedation score was evaluated at an interval of 20 minutes. If it did not reach 0 or below, an additional spray of 25µg dexmed
Group A:In Group A, the RASS-PAL sedation score was evaluated at an interval of 10 minutes. If it did not reach 0 or below, an additional spray of 25µg dexmed
Group C:In Group C, the RASS-PAL sedation score was evaluated at an interval of 30 minutes. If it did not reach 0 or below, an additional spray of 25µg dexmed
Sponsors
Zhejiang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.The age should be no less than 18 years old; 2.The patient must be diagnosed by an oncologist or a doctor trained in palliative care as being in the terminal stage of a malignant tumor; 3.Terminal patients who have received systematic palliative care and are willing to receive palliative sedation treatment; 4.Do not perform invasive cardiopulmonary resuscitation surgeries, such as tracheal intubation, cardiac compression or ventilator-assisted ventilation;
Exclusion criteria
Exclusion criteria: 1.Researchers consider subjects who are not suitable for nasal spray administration (such as those with severe rhinitis, nasal deformities, nasogastric feeding patients, etc.); 2.Patients for whom detailed sedation and vital signs cannot be obtained; 3.Selective a 2-adrenergic receptor agonists (clonidine) or antagonists (such as phenbenzamine, etc.) were used within 7 days prior to randomization. 4.Patients with a history of heart failure who have undergone inpatient or outpatient examinations in the past 12 months and those with known severe left ventricular dysfunction (defined as a known echocardiographic left ventricular ejection fraction <20%); 5.Subjects with unclear consciousness and mental system disorders; 6.Allergic to dexmedetomidine; 7.Patients who are currently participating in or planning to participate in any interventional clinical trials; 8.The researchers believe that there are any other reasons that make the patient unsuitable to participate in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of sedation;Success rate of sedation; | — |
Secondary
| Measure | Time frame |
|---|---|
| 32/5000 Incidence of adverse events (hypotension, bradycardia, arrhythmia, sinus arrest, hypertension, etc.);Pain score and dosage of analgesic drugs; | — |
Countries
China
Contacts
Public ContactYanfei Xia
Zhejiang Hospital
Outcome results
None listed